Study finds potential benefits and risks of weight-loss drugs in 2 million people
economictimes.indiatimes.com — January 21, 2025, 07:01 AM UTC
A new study in Nature Medicine analyzed health data from 2.4 million diabetic individuals, revealing that GLP-1 receptor agonists, commonly used for weight loss and diabetes, may also lower risks for neurocognitive disorders and cardiovascular diseases. While the drugs showed benefits, including reduced risks for conditions like Alzheimer’s and heart disease, they were also linked to increased gastrointestinal issues and other complications. The findings highlight the need for further clinical trials to confirm these results. Researchers caution against viewing GLP-1RAs as a universal treatment, as the study primarily involved older men. More research is needed to explore their effects on different populations and health issues.